Inhibition of human telomerase by diphosphates of acyclic nucleoside phosphonates

Diphosphates of the antiviral acyclic nucleoside phosphonates (ANPs) were evaluated in telomeric repeat amplification protocol (TRAP) for their ability to inhibit the extension of telomeres by human telomerase. Extracts from human leukaemia HL-60 cells were used as a source of the enzyme. Data show that the most effective compound studied was the guanine derivative PMEGpp (IC50 12.7 ± 0.5 μmol L−1 at 125 μmol L−1 deoxynucleoside triphosphates (dNTPs)). The inhibitory effects of other PME, PMP and HPMP diphosphates on telomerase reverse transcriptase decreased in the order: (R)-PMPGpp > (R)-HPMPGpp > PMEDAPpp > (S)-PMPGpp > (S)-HPMPApp > PMEO-DAPypp > (R)-6-cyprPMPDAPpp > (R)-PMPApp > (R)-PMPDAPpp ≥ PMEApp ≥ PMECpp > PMETpp > (S)-PMPApp ∼ 6-Me2PMEDAPpp. These results are consistent with the observed antineoplastic activities of the parental guanine (PMEG) and 2,6-diaminopurine (PMEDAP) PME-derivatives. Moreover, structure-activity relationship indicates enantioselectivity of some of these human telomerase inhibitors: (R)-isomers of the PMP-derivatives possess stronger inhibitory potency towards the enzyme than (S)-isomers. The data may contribute to the rational design of telomerase inhibitors based on the structure of acyclic nucleotide analogues.